Blair et al. proposed a therapeutic strategy that combines PEGPH20 with GVAX (a granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transfected tumor cell vaccine), and proved that the single agent GVAX upregulates myeloid C-X-C chemokine receptor 4 (CXCR4) expression, while combined PEGPH20 modifying HA can decrease the CXCL12/CXCR4/chemokine receptor 7 (CCR7) immunosuppressive signaling axis, thus regulating myeloid cells, increasing T cell infiltration, and inducing memory effector T cells in PDAC. The gene discussed is CSF2; the disease is neoplasm.